Key facts
- This page summarizes William R. Elder's Form 4 filing for Diffusion Pharmaceuticals Inc. (CRVO).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 22 Mar 2022, 07:30.
William R. Elder - 18 Mar 2022 Form 4 Insider Report for Diffusion Pharmaceuticals Inc. (CRVO)
- Reporting relationship
- GC & Secretary
- Issuer ticker
- CRVO
- Reported as of
- 18 Mar 2022
- Net transaction value
- +$2,500
- SEC form
- 4
- Accepted by SEC
- 22 Mar 2022, 07:30:54 UTC
- Prior SEC filing
- 31 Jan 2022
- Next SEC filing
- 19 Apr 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ William R. Elder
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
William R. Elder filed Form 4 for Diffusion Pharmaceuticals Inc. (CRVO) on 22 Mar 2022.
Change
- Previous filing in this sequence was filed on 31 Jan 2022.
- Current net transaction value: +$2,500.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DFFN
transaction
Derivative
Series C Convertible Preferred Stock
Purchase
- Transaction value
- $2,500
- Shares
- +5,000
- Change %
- Price
- $0.5000
- Shares after
- 5,000
- Date
- 18 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,000
- Exercise price
- $0.5000
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
1. On March 18, 2022, the Reporting Person purchased 5,000 shares of Series C Convertible Preferred Stock, par value $0.001 per share (the "Shares"), from the Issuer at a purchase price of $0.50 per Share in a private placement. The Shares have no voting rights, other than (i) each Share will be counted on an as converted basis, together with the Issuer's common stock as a single class, for purposes of determining the presence of a quorum at any meeting of the Issuer's stockholders at which a proposal related to a reverse stock split of the Issuer's common stock (a "Reverse Stock Split") will be voted upon, (ii) each Share is entitled to 80,000 votes on matters related to a Reverse Stock Split, provided that such votes must be cast For and Against each proposal on a "mirrored" basis proportional to the vote of the Issuer's common stockholders, and (iii) the right to vote as a class on certain specified matters directly related to the preferences, rights, and limitations of the Shares.